Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2015

01-01-2015 | Preclinical study

A genetic variant at 12p11 significantly modifies breast cancer risk in a genetically homogenous island population

Authors: Terri Patricia McVeigh, Una Mary McVeigh, Karl J. Sweeney, Michael J. Kerin, Nicola Miller

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Login to get access

Abstract

Genome-wide association studies have identified novel breast cancer susceptibility loci at 12q24 (rs1292011), 12p11 (rs10771399) and 21q21 (rs2823093). The aim of our study was to investigate the prevalence of variants at these three loci in an Irish sample, and to examine the association between these variants and breast cancer in this cohort. DNA was extracted from the blood or buccal swabs of Irish patients with breast cancer (cases), as well as from healthy Irish female controls. Genotyping was performed for each target using a Taqman-based platform. Data were analysed using IBM Statistical Package for the Social Sciences version 22. Genotyping was performed on samples from 1,267 patients with breast cancer and 841 cancer-free controls. The per-allele odds ratio associated with the minor allele at 12p11 was found to be 0.67 (0.54–0.81, p < 0.001). Genotype-specific odds ratios showed an allele dosage effect with odds ratio of 0.76 (0.6–0.95) for heterozygotes, and 0.23 (0.1–0.51) for rare homozygotes. Minor allele frequencies of the variants at 12q24 and 21q21 did not differ significantly between cases or controls. All three investigated variants were identified in the Irish population. The polymorphism rs10771399 was strongly associated with breast cancer risk in this cohort, and was shown to be associated with reduced odds ratio for all molecular subtypes.
Literature
1.
go back to reference Ponder BAJ, Day NE, Easton DF, Pharoah PDP, Lipscombe JM, Redman K, Antoniou A, Basham V, Gregory J, Gayther S, Dunning A (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301–1308CrossRef Ponder BAJ, Day NE, Easton DF, Pharoah PDP, Lipscombe JM, Redman K, Antoniou A, Basham V, Gregory J, Gayther S, Dunning A (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301–1308CrossRef
2.
go back to reference Smith P, McGuffog L, Easton DF et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45(7):646–655PubMedCentralPubMedCrossRef Smith P, McGuffog L, Easton DF et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45(7):646–655PubMedCentralPubMedCrossRef
3.
go back to reference Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33–36PubMedCrossRef Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33–36PubMedCrossRef
4.
go back to reference Ghoussaini M, Pharoah PDP, Easton DF (2013) Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning? Am J Pathol 183(4):1038–1051PubMedCrossRef Ghoussaini M, Pharoah PDP, Easton DF (2013) Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning? Am J Pathol 183(4):1038–1051PubMedCrossRef
5.
go back to reference Ghoussaini M, Fletcher O, Michailidou K et al (2012) Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 44(3):312–318PubMedCentralPubMedCrossRef Ghoussaini M, Fletcher O, Michailidou K et al (2012) Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 44(3):312–318PubMedCentralPubMedCrossRef
7.
go back to reference Horwitz MJ, Stewart AF (2006) Hypercalcemia associated with malignancy. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn. American Society of Bone and Mineral Research, Washington DC Horwitz MJ, Stewart AF (2006) Hypercalcemia associated with malignancy. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn. American Society of Bone and Mineral Research, Washington DC
8.
go back to reference Sloan EK, Anderson RL (2002) Genes involved in breast cancer metastasis to bone. Cell Mol Life Sci 59(9):1491–1502PubMedCrossRef Sloan EK, Anderson RL (2002) Genes involved in breast cancer metastasis to bone. Cell Mol Life Sci 59(9):1491–1502PubMedCrossRef
9.
go back to reference Mula RV, Bhatia V, Falzon M (2010) PTHrP promotes colon cancer cell migration and invasion in an integrin alpha6beta4-dependent manner through activation of Rac1. Cancer Lett 298(1):119–127PubMedCentralPubMedCrossRef Mula RV, Bhatia V, Falzon M (2010) PTHrP promotes colon cancer cell migration and invasion in an integrin alpha6beta4-dependent manner through activation of Rac1. Cancer Lett 298(1):119–127PubMedCentralPubMedCrossRef
10.
go back to reference Qin Z, Wang Y, Cao S, He Y, Ma H, Jin G, Hu Z, Guan X, Shen H (2013) Genetic variants at 12p11 and 12q24 are associated with breast cancer risk in a Chinese population. PLoS ONE 8(6):e66519PubMedCentralPubMedCrossRef Qin Z, Wang Y, Cao S, He Y, Ma H, Jin G, Hu Z, Guan X, Shen H (2013) Genetic variants at 12p11 and 12q24 are associated with breast cancer risk in a Chinese population. PLoS ONE 8(6):e66519PubMedCentralPubMedCrossRef
11.
go back to reference Antoniou AC, Kuchenbaecker KB, Soucy P et al (2012) Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 14(1):R33PubMedCentralPubMedCrossRef Antoniou AC, Kuchenbaecker KB, Soucy P et al (2012) Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 14(1):R33PubMedCentralPubMedCrossRef
12.
go back to reference Lin J, Ding L, Jin R, Zhang H, Cheng L, Qin X, Chai J, Ye Q (2009) Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140 kDa (RIP140) interact and cooperate in estrogen signaling. Int J Biochem Cell Biol 41(7):1613–1618PubMedCrossRef Lin J, Ding L, Jin R, Zhang H, Cheng L, Qin X, Chai J, Ye Q (2009) Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140 kDa (RIP140) interact and cooperate in estrogen signaling. Int J Biochem Cell Biol 41(7):1613–1618PubMedCrossRef
13.
go back to reference McVeigh TP, Irwin R, Cody N, Miller N, McDevitt T, Sweeney KJ, Green AJ, Kerin MJ (2014) Familial breast cancer genetic testing in the West of Ireland. Ir J Med Sci 183(2):199–206PubMedCrossRef McVeigh TP, Irwin R, Cody N, Miller N, McDevitt T, Sweeney KJ, Green AJ, Kerin MJ (2014) Familial breast cancer genetic testing in the West of Ireland. Ir J Med Sci 183(2):199–206PubMedCrossRef
14.
go back to reference Beral V, Bull D, Doll R, Peto R, Reeves G (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef Beral V, Bull D, Doll R, Peto R, Reeves G (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef
15.
go back to reference Shapiro SS (1964) An analysis of variance test for normality (complete samples) Shapiro SS (1964) An analysis of variance test for normality (complete samples)
16.
go back to reference Rodriguez S, Gaunt TR, Day INM (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169(4):505–514PubMedCentralPubMedCrossRef Rodriguez S, Gaunt TR, Day INM (2009) Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169(4):505–514PubMedCentralPubMedCrossRef
20.
21.
22.
go back to reference O’Dushlaine CT, Morris D, Moskvina V, Kirov G, Gill M, Corvin A, Wilson JF, Cavalleri GL (2010) Population structure and genome-wide patterns of variation in Ireland and Britain. Eur J Hum Genet 18(11):1248–1254PubMedCentralPubMedCrossRef O’Dushlaine CT, Morris D, Moskvina V, Kirov G, Gill M, Corvin A, Wilson JF, Cavalleri GL (2010) Population structure and genome-wide patterns of variation in Ireland and Britain. Eur J Hum Genet 18(11):1248–1254PubMedCentralPubMedCrossRef
23.
go back to reference Novembre J, Johnson T, Bryc K, Kutalik Z, Boyko AR, Auton A, Indap A, King KS, Bergmann S, Nelson MR, Stephens M, Bustamante CD (2008) Genes mirror geography within Europe. Nature 456(7218):98–101PubMedCentralPubMedCrossRef Novembre J, Johnson T, Bryc K, Kutalik Z, Boyko AR, Auton A, Indap A, King KS, Bergmann S, Nelson MR, Stephens M, Bustamante CD (2008) Genes mirror geography within Europe. Nature 456(7218):98–101PubMedCentralPubMedCrossRef
24.
25.
go back to reference Hill EW, Jobling MA, Bradley DG (2000) Y-chromosome variation and Irish origins. Nature 404(6776):351–352PubMedCrossRef Hill EW, Jobling MA, Bradley DG (2000) Y-chromosome variation and Irish origins. Nature 404(6776):351–352PubMedCrossRef
26.
27.
go back to reference Coss KP, Doran PP, Owoeye C, Codd MB, Hamid N, Mayne PD, Crushell E, Knerr I, Monavari AA, Treacy EP (2013) Classical galactosaemia in Ireland: incidence, complications and outcomes of treatment. J Inherit Metab Dis 36(1):21–27PubMedCrossRef Coss KP, Doran PP, Owoeye C, Codd MB, Hamid N, Mayne PD, Crushell E, Knerr I, Monavari AA, Treacy EP (2013) Classical galactosaemia in Ireland: incidence, complications and outcomes of treatment. J Inherit Metab Dis 36(1):21–27PubMedCrossRef
28.
go back to reference Farrell PM, Joffe S, Foley L, Canny GJ, Mayne P, Rosenberg M (2007) Diagnosis of cystic fibrosis in the Republic of Ireland: epidemiology and costs. Ir Med J 100(8):557PubMed Farrell PM, Joffe S, Foley L, Canny GJ, Mayne P, Rosenberg M (2007) Diagnosis of cystic fibrosis in the Republic of Ireland: epidemiology and costs. Ir Med J 100(8):557PubMed
29.
go back to reference Ryan E, O’Keane C, Crowe J (1998) Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 24(4):428–432PubMedCrossRef Ryan E, O’Keane C, Crowe J (1998) Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis 24(4):428–432PubMedCrossRef
30.
go back to reference Eisensmith RC, Goltsov AA, O’Neill C et al (1995) Recurrence of the R408 W mutation in the phenylalanine hydroxylase locus in Europeans. Am J Hum Genet 56(1):278–286PubMedCentralPubMed Eisensmith RC, Goltsov AA, O’Neill C et al (1995) Recurrence of the R408 W mutation in the phenylalanine hydroxylase locus in Europeans. Am J Hum Genet 56(1):278–286PubMedCentralPubMed
31.
go back to reference Ramus SJ, Treacy EP, Cotton RGH (1995) Characterization of phenylalanine hydroxylase alleles in untreated phenylketonuria patients from Victoria, Australia: origin of alleles and haplotypes. Am J Hum Genet 56(5):1034–1041PubMedCentralPubMed Ramus SJ, Treacy EP, Cotton RGH (1995) Characterization of phenylalanine hydroxylase alleles in untreated phenylketonuria patients from Victoria, Australia: origin of alleles and haplotypes. Am J Hum Genet 56(5):1034–1041PubMedCentralPubMed
34.
go back to reference Vallone PM, Butler JM (2004) Y-SNP typing of U.S. African American and Caucasian samples using allele-specific hybridization and primer extension. J Forensic Sci 49(4):723–732PubMedCrossRef Vallone PM, Butler JM (2004) Y-SNP typing of U.S. African American and Caucasian samples using allele-specific hybridization and primer extension. J Forensic Sci 49(4):723–732PubMedCrossRef
Metadata
Title
A genetic variant at 12p11 significantly modifies breast cancer risk in a genetically homogenous island population
Authors
Terri Patricia McVeigh
Una Mary McVeigh
Karl J. Sweeney
Michael J. Kerin
Nicola Miller
Publication date
01-01-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3222-1

Other articles of this Issue 1/2015

Breast Cancer Research and Treatment 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine